Aridis Pharmaceuticals (ARDS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	535.00 k	535.00 k	535.00 k	535.00 k	535.00 k	535.00 k
Cash burn (monthly)	(no burn)	216.50 k	289.67 k	73.58 k	327.67 k	1.49 mm
Cash used (since last report)	n/a	3.21 mm	4.29 mm	1.09 mm	4.86 mm	22.09 mm
Cash remaining	n/a	-2.67 mm	-3.76 mm	-555.37 k	-4.32 mm	-21.55 mm
Runway (months of cash)	n/a	-12.3	-13.0	-7.5	-13.2	-14.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2023

ARDS institutional ownership history Ownership history

24.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	22	25	-12.0%
Opened positions	3	9	-66.7%
Closed positions	6	3	+100.0%
Increased positions	4	2	+100.0%
Reduced positions	1	5	-80.0%

13F shares	Current	Prev Q	Change
Total value	240.35 mm	1.10 bn	-78.1%
Total shares	11.03 mm	13.37 mm	-17.5%
Total puts	0.00	0.00
Total calls	19.00 k	24.50 k	-22.4%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Cystic Fibrosis Foundation	5.17 mm	$5.12 mm	0.0%
Lind Global Fund II	3.00 mm	$1.13 mm	0.0%
AZN AstraZeneca	884.96 k	$0.00	0.0%
Commonwealth Equity Services	646.00 k	$142.00 k	0.0%
Roumell Asset Management	446.59 k	$98.21 mm	0.0%
STT State Street	202.25 k	$44.47 mm	+367.7%
Geode Capital Management	143.03 k	$31.45 mm	0.0%
Francis Capital Management	142.84 k	$0.00	0.0%
Vanguard	136.20 k	$29.95 mm	-74.1%
HRT Financial	73.72 k	$16.00 k	+328.0%

Largest transactions	Shares	Bought/sold	Change
Sabby Management	0.00	-2.14 mm	EXIT
Vanguard	136.20 k	-388.96 k	-74.1%
STT State Street	202.25 k	+159.00 k	+367.7%
HRT Financial	73.72 k	+56.50 k	+328.0%
PRU Prudential Financial	0.00	-37.60 k	EXIT
Susquehanna International	0.00	-23.08 k	EXIT
Cornerstone Wealth Management	20.00 k	+20.00 k	NEW
Jane Street	0.00	-15.36 k	EXIT
Tower Research Capital	16.36 k	+14.78 k	+933.0%
Virtu Financial	11.81 k	+11.81 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ARDS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jun 24	Hasan Jafri	Stock options Common Stock	Grant	Acquire A	No	No	0.063	250,000	15.75 k	382,495
27 Jun 24	John F Hamilton	Stock options Common Stock	Grant	Acquire A	No	No	0.063	200,000	12.60 k	269,040
27 Jun 24	Susan Richards Windham-Bannister	Stock options Common Stock	Grant	Acquire A	No	No	0.063	200,000	12.60 k	261,000
24 Jun 24	Vu Truong	Common stock purchase	Buy	Acquire P	No	No	0.07	714,286	50.00 k	1,378,639
24 Jun 24	Eric Patzer	Common stock purchase	Buy	Acquire P	No	No	0.07	714,286	50.00 k	884,600

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Aridis Provides Corporate Update

20 Dec 24

LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC:ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments. Company